U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

PubAg

Main content area

Alpha-1 Antitrypsin Gene Therapy Prevented Bone Loss in Ovariectomy Induced Osteoporosis Mouse Model

Author:
Mohammad Ahsanul Akbar, Jay Cao, Yuanqing Lu, David Nardo, Mong-Jen Chen, Ahmed S. Elshikha, Rubina Ahamed, Mark Brantly, L. Shannon Holliday, Sihong Song
Source:
Human gene therapy 2016 v.27 pp. 1-8
ISSN:
1043-0342
Subject:
adults, animal models, anti-inflammatory activity, biomarkers, blood serum, bone resorption, bone strength, gene expression, gene therapy, health services, humans, interleukin-6, mice, osteoporosis, ovariectomy, pathogenesis, phosphates, postmenopause, proteins, risk, viruses, women
Abstract:
Osteoporosis is a major healthcare burden affecting mostly postmenopausal women characterized by compromised bone strength and increased risk of fragility fracture. Although pathogenesis of this disease is complex, elevated proinflammatory cytokine production is clearly involved in bone loss at menopause. Therefore, anti-inflammatory strategies hold a great potential for the prevention of postmenopausal osteoporosis. In this study, we investigated the effect of gene therapy of recombinant adeno-associated virus (rAAV)–mediated human alpha-1 antitrypsin (hAAT), a multifunctional protein that has anti-inflammatory property, on bone loss in an ovariectomy-induced osteoporosis mouse model. Adult ovariectomized (OVX) mice were intraperitoneally (i.p.) injected with hAAT (protein therapy), rAAV8-CB-hAAT (gene therapy), or phosphate buffer saline (PBS). Age-matched and sham-operated animals were used as controls. Eight weeks after the treatment, animals were sacrificed and bone-related biomarkers and vertebral bone structure were evaluated. Results showed that hAAT gene therapy significantly decreased serum IL-6 level and receptor activator of NF-jB (RANK) gene expression in bone. Importantly, hAAT gene therapy increased bone volume/total volume and decreased structure model index (SMI) compared to PBS injection in OVX mice. These results demonstrate that hAAT gene therapy by rAAV vector efficiently mitigates bone loss possibly through inhibition of proinflammatory cytokine IL-6 and RANK gene expression. Considering the safety profile of hAAT and rAAV vector in humans, our results provide a new alternative for the treatment of osteoporosis.
Agid:
62932
Handle:
10113/62932